US and Europe Atopic Dermatitis Market: By Drug Class (Immunosuppressants, PDE-4 Inhibitor, Antihistamines, Antibiotics, Biologic Therapy, Calcineurin Inhibitors, Corticosteroids, Emollients, Others), By Route Of Administration (Injectables, Oral, Topical), By Distribution Channel (Hospital Pharmacies, Online pharmacies, Drug stores, Retail pharmacies) and Country

US and Europe Atopic Dermatitis Market size was valued at USD x billion in 2022 and is poised to grow at a CAGR of x% from 2023-29. The U.S. and Europe atopic dermatitis market is growing at a significant CAGR due to change in lifestyle, increase in atopic dermatitis population, and pollution and climatic changes. Growing prevalence of the food allergies and growing focus on new therapies are the key factors drive the U.S. and Europe atopic dermatitis market growth. Furthermore, increase in use of pharmacological products in developed countries. Increase in R&D expenditure to develop novel biologics, and improvement in healthcare expenditure might increase the growth of U.S. and Europe atopic dermatitis market over the forecast period. However, the challenge is time to be taken in drug adoption, high price and legal regulations might hamper the growth of the market. Similarly, highly generalized nature of the atopic dermatitis market and lack of awareness on drug usage hinder the growth of U.S. and Europe atopic dermatitis market over the forecast period. Atopic dermatitis primarily effects in infants, children, and also rarely effects in the adult population. Atopic dermatitis is associated with inhalant allergies (such as hay fever), asthma, and chronic dermatitis. In atopic dermatitis condition, the skin becomes inflamed and extremely itchy, that causes cracking, redness, weeping, vesicle formation, swelling, scaling, and crushing. The common risk factors for atopic dermatitis are inhalant allergens, food allergens, exposure to harsh soaps and detergents, and cold weather, and sometimes it causes due to genetics or heritability. People living in dry climate are more likely to get affected with atopic dermatitis.

US and Europe Atopic Dermatitis Market Key Developments:

• In March 2017, U.S. FDA approved Regeneron/Sanofi anti-Interleukin-4R-alpha mAb Dupixent (Dupilumab) used in the treatment of atopic dermatitis.
• In February 2016, Otsuka Pharmaceutical Co., Ltd. and Medimetriks Pharmaceuticals, Inc. announced that they entered into a licensing agreement. The agreement provides Medimetriks, with development, marketing and manufacturing rights to OPA-15406 in the United States.